IWM
ACAD icon

IHT Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

IHT Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-117
Closed -$2K – 413
2018
Q1 		$2K Hold
117
– – ﹤0.01% 1477
2017
Q4 		$3K Buy
117
+100
+588% +$3.2K ﹤0.01% 1410
2017
Q3 		$1K Buy
+17
New +$553 ﹤0.01% 1274

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

IHT Wealth Management's ACAD Position: Q2 2018 in Review

IHT Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 117 shares — an estimated $2K sold.

IHT Wealth Management first reported a position in ACAD in Q3 2017 and held it in 3 quarters. The position peaked at $3K in Q4 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • IHT Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 117 Acadia Pharmaceuticals shares in Q2 2018, an estimated $2K.
  • IHT Wealth Management first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • IHT Wealth Management's Acadia Pharmaceuticals position peaked at $3K in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.